Potential clinical applications of interleukin-12

Current Opinion in Hematology

Volumn 3, Issue 3, 1996, Pages 216-222

  Chougnet, Claire ^a   Shearer, Gene M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; INTERLEUKIN RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNITY; BACTERIAL INFECTION; CANCER THERAPY; CLINICAL TRIAL; ETIOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; INFECTION; NATURAL KILLER CELL; NONHUMAN; PARASITOSIS; PRIORITY JOURNAL; REVIEW; SHWARTZMAN PHENOMENON; T LYMPHOCYTE; TUBERCULOUS PLEURISY; VIRUS REPLICATION;

EID: 0029946526     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199603030-00009     Document Type: Review

References (70)

1. Gubler U, Chua AO, Schoenhaut DS, Dwyer CM, McComas W, Motyka R, Nabavi N, Wolitzky AG, Quinn PM, Familletti PC, Gately MK: Compression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci USA 1991, 88:4143-4147.
2. D'Andrea A, Rengaraju M, Valiante NM, Chehimi J, Kubin M, Aste M, Chan SH, Kobayashi M, Young D, Nickbarg E, Chizzonite R, Wolf SF, Trinchieri G: Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med 1992, 176:1387-1398.
3. Macatonia SE, Hosken NA, Litton M, Vieira P, Hsieh CS, Culpepper JA, • Wysocka M, Trinchieri G, Murphy KM, O'Garra A: Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol 1995, 154:5071-5079. The authors demonstrate that dendritic cells can produce interleukin-12 and that this production is enhanced by culture with activated T cells. This finding suggests that by their production of interleukin-12, dendritic cells play a role in the development of Th1 cells.
4. Cassatella MA, Meda L, Gasperini S, D'Andrea A, Ma X, Trinchieri G: Interleukin-12 production by human polymorphonuclear leukocytes. Eur J Immunol 1995, 25:1-5.
5. Muller G, Saloga J, Germann T, Bellinghausen I, Mohamadzadeh M, Knop J, Enk AH: Identification and Induction of human keratinocyte-derived IL-12. J Clin Invest 1994, 94:1799-1805.
6. D'Andrea A, Aste AM, Valiante NM, Ma X, Kubin M, Trinchieri G: Interleukin 10 (IL-10) inhibits human lymphocyte Interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis In accessory cells. J Exp Med 1993, 178:1041-1048.
7. Hayes MP, Wang J, Norcross MA: Regulation of interleukin-12 expression in human monocytes: selective priming by Interferon-gamma of lipopolysaccharide-inducible p35 and p40 genes. Blood 1995, 86:646-650.
8. Shu U, Kiniwa M, Wu CY, Maliszewski C, Vezzio N, Hakimi J, Gately M, • Delespesse G: Activated T cells induce interleukin-12 production by monocytes via CD40-CD40 ligand interaction. Eur J Immunol 1995, 25:1125-1128. The authors demonstrate that, in the absence of other stimuli, monocytes/macrophages can produce interleukin-12 if cultured in presence of activated T cells that express high levels of CD40 ligand.
9. Paul WE, Seder RA: Lymphocyte responses and cytokines. Cell 1994, 76:241-251.
10. Manetti R, Gerosa F, Giudizi MG, Biagiotti R, Parronchi P, Piccinni MP, Sampognaro S, Maggi E, Romagnani S, Trinchieri G, et al.: Interleukin 12 induces stable priming for Interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones. J Exp Med 1994, 179:1273-1283.
11. + allergen-specific Th2 T cell clones, Int Immunol 1994, 6:1091-1096.
12. Chouaib S, Chehimi J, Bani L, Genetet N, Tursz T, Gay F, Trinchieri G, Mami CF: Interleukin 12 induces the differentiation of major histocompatibllity complex class I-primed cytotoxic T-lymphocyte precursors into allospecific cytotoxic effectors. Proc Natl Acad Sci USA 1994, 91:12659-12663.
13. Aste AM, D'Andrea A, Kubin M, Trinchieri G: Cooperation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules In human T and NK cells. Cell Immunol 1994, 156:480-492.
14. McKnight AJ, Zimmer GJ, Fogelman I, Wolf SF, Abbas AK: Effects of IL-12 on helper T cell-dependent immune responses in vivo. J Immunol 1994, 152:2172-2179.
15. Kiniwa M, Gately M, Gubler U, Chizzonite R, Fargeas C, Delespesse G: Recombinant interleukin-12 suppresses the synthesis of Immunoglobulin E by interleukin-4 stimulated human lymphocytes. J Clin Invest 1992, 90:262-266.
16. Morris SC, Madden KB, Adamovicz JJ, Cause WC, Hubbard BR, Gately MK, Finkelman FD: Effects of IL-12 on in vivo cytokine gene expression and Ig Isotype selection. J Immunol 1994, 152:1047-1056.
17. Chizzonite R, Truitt T, Desai BB, Nunes P, Podlaski FJ, Stern AS. Gately MK: IL-12 receptor. I. Characterization of the receptor on phytohemagglutinin-activated human lymphoblasts. J Immunol 1992, 148:3117-3124.
18. Desai BB, Quinn PM, Wolitzky AG, Mongini PK, Chizzonite R, Gately MK: IL-12 receptor. II. Distribution and regulation of receptor expression. J Immunol 1992, 148:3125-3132.
19. Chua AO, Chizzonite R, Desai BB, Truitt TP, Nunes P, Minetti LJ, Warrier RR, Presky DH, Levine JF, Gately MK, et al.: Expression cloning of a human IL-12 receptor component A new member of the cytokine receptor superfamily with strong homology to gp130. J Immunol 1994, 153:128-136.
20. Bellone G, Trinchieri G: Dual stimulatory and inhibitory effect of NK cell stimulatory factor/IL-12 on human hematopoiesis. J Immunol 1994, 153:930-937.
21. Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK: Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 1993,177:1505-1509.
22. Sypek JP, Chung CL, Mayor SE, Subramanyam JM, Goldman SJ, Sieburth DS, Wolf SF, Schaub RG: Resolution of cutaneous leishmaniasis: Interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med 1993, 177:1797-1802.
23. Wang ZE, Zheng S, Corry DB, Dalton DK, Seder RA, Reiner SL, Locksley RM: Interferon gamma-independent effects of Interleukin 12 administered during acute or established infection due to Leishmania major. Proc Natl Acad Sci U S A 1994, 91:12932-12936.
24. Nabors GS, Afonso LCC, Farrell JP, Scott P: Switch from a type 2 to a • type 1 T helper cell response and cure of established Leishmania major Infection In mice is induced by combined therapy with interleukln 12 and Pentostam. Proc Natl Acad Sci U S A 1995, 92:3142-3146. The authors use infection with L. major in susceptible BALB/c mice as a model to investigate the requirements for switching an established Th2 response to a Th1 response. Treatment with interleukin-12 in combination with the anti-leishmanial drug, Pentostam, induces healing of established lesions. In contrast, treatment with either interleukin-12 or Pentostam alone did not result in healing. That healing is associated with a switch from a Th2 to a Th1 response, indicating that, at the population level, dominance of the Th2 subset can be altered.
25. Oswald IP, Caspar P, Jankovic D, Wynn TA, Pearce EJ, Sher A: IL-12 Inhibits Th2 cytokine responses induced by eggs of Schistosoma mansoni. J Immunol 1994, 153:1707-1713.
26. Wynn TA, Eltoum I, Oswald IP, Cheever AW, Sher A: Endogenous inter • leukin 12 (IL-12) regulates granuloma formation induced by eggs of Schistosoma mansoni and exogenous IL-12 both Inhibits and prophylactically immunizes against egg pathology. J Exp Med 1994, 179:1551-1561. Treatment with interleukin-12 profoundly inhibited primary and secondary granuloma formation induced by eggs of S. mansoni. Moreover, this paper reported that mice sensitized with eggs, in combination with interleukin-12, developed minimal pathology on subsequent challenge, suggesting that interleukin-12 may be used for therapeutic and prophylactic purposes in this model.
27. Gazzinelli RT, Hieny S, Wynn TA, Wolf S, Sher A: Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc Natl Acad Sci U S A 1993, 90:6115-6119.
28. Khan IA, Matsuura T, Kasper LH: Interleukin-12 enhances murine survival against acute toxoplasmosis. Infect Immun 1994, 62:1639-1642.
29. Hunter CA, Candolfi E, Subauste C, Van CV, Remington JS: Studies on the role of interleukin-12 In acute murine toxoplasmosis. Immunology 1995, 84:16-20.
30. Stevenson MM, Fong Tam M, Wolf SW, Sher A: IL-12-induced protection against blood-stage Plasmodium chabaudi AS requires IFN-γ and TNF-α and occurs via a nitric oxide-dependent mechanism. J Immunol 1995, 155:2545-2556.
31. Flynn JL, Goldstein MM, Tnebold KJ, Sypek J, Wolf S, Bloom BR: IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis Infection. J Immunol 1995, 155:2515-2524.
32. Gil Castro A, Silva RA, Appelberg R: Endogenously produced IL-12 is required for the induction of protective T cells during Mycobacterium avium infections in mice. J Immunol 1995, 155:2013-2019.
33. Tripp CS, Kanagawa O, Unanue ER: Secondary response to Listeria infection requires IFN-gamma but is partially independent of IL-12. J Immunol 1995, 155:3427-3432.
34. Ozmen L, Aguet M, Trinchieri G, Garotta G: The in vivo antiviral activity of interleukin-12 is mediated by gamma Interferon. J Virol 1995, 69:8147-8150.
35. Orange JS, Wang B, Terhorst C, Biron CA: Requirement for natural killer cell-produced Interferon gamma In defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration. J Exp Med 1995, 182:1045-1056.
36. Orange JS, Wolf SF, Biron CA: Effects of IL-12 on the response and •• susceptibility to experimental viral infections. J Immunol 1994, 152:1253-1264. Effects of exogenous interleukin-12 on immune responses to lymphocytic choriomeningitis virus are described. Low doses of interteukin-12 enhanced immunity to virus. In contrast, high doses were detrimental to resistance against lymphocytic choriomeningitis virus infection and were toxic to the infected mice. This paper demonstrates that interleukin-12 effects depend on the dose and the environment in which this cytokine is given.
37. Orange JS, Salazar MT, Opal SM, Spencer RL, Miller AH, McEwen BS, Biron CA: Mechanism of interleukin 12-mediated toxiclties during experimental viral Infections: role of tumor necrosis factor and glucocorticoids. J Exp Med 1995, 181:901-914.
38. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ, Lotze MT: Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 1994, 153:1697-1706.
39. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993, 178:1223-1230.
40. Mu J, Zou JP, Yamamoto N, Tsutsui T, Tai XG, Kobayashi M, Herrmann S, Fujiwara H, Hamaoka T: Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizlng spontaneously to lung and lymph nodes. Cancer Res 1995, 55:4404-4408.
41. Stem LL, Tarby CM, Tamborini B, Truitt GA: Preclinical development of IL-12 as an anticancer drug: comparison to IL-2 [abstract]. Proc Annu Meet Am Assoc Cancer Res 1994, 35:310a.
42. Zitvogel L, Tahara H, Robbins PD, Storkus WJ, Clarke MR, Nalesnik MA, •• Lotze MT: Cancer Immunotherapy of established tumors with IL-12: effective delivery by genetically engineered fibroblasts. J Immunol 1995, 155:1393-1403. This paper demonstrates that paracrine delivery of interleukin-12, using autologous or allogeneic fibroblasts genetically engineered to secrete high levels of interleukin-12, reduced established tumors and induced long-term protective antitumor immunity without side effects.
43. Tahara H, Zitvogel L, Storkus WJ, Zeh H3, McKinney TG, Schreiber RD, Gubler U, Robbins PD, Lotze MT: Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retrovlral vector. J Immunol 1995, 154:6466-6474.
44. Brunda MJ, Luistro L, Hendrzak JA, Fountoulakis M, Garotta G, Gately MK: Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12. J Immunother 1995, 17:71-77.
45. Fujiwara H, Zou JP, Herrmann S, Hamaoka T: IL-12-induced tumor regression depends on striking reversal of suppressed IFN-γ production by anti-tumor T cells, their accumulation to tumor sites and in situ IFN-γ production. Res Immunol 1995, 146:638-643.
46. Chehimi J, Starr SE, Frank I, D'Andrea A, Ma X, MacGregor RR, Sennelier J, Trinchieri G: Impaired interleukin 12 production in human immunodeficiency virus-infected patients. J Exp Med 1994, 179:1361-1366.
47. Chehimi J, Starr SE, Frank I, Rengaraju M, Jackson SJ, Llanes C, Kobayashi M, Perussia B, Young D, Nickbarg E, Trinchieri G: Natural killer (NK) cell stimulatory factor increases the cytotoxlc activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients. J Exp Med 1992, 175:789-796.
48. Clerici M, Lucey DR, Berzofsky JA, Pinto LA, Wynn TA, Blatt SP, Dolan MJ, Hendrix CW, Wolf SF, Shearer GM: Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science 1993, 262:1721-1724.
49. Oyaizu N, Pahwa S: Role of apoptosis In HIV disease pathogenesis. J Clin Immunol 1995, 15:217-231.
50. Clerici M, Sarin A, Coffman RL, Wynn TA, Blatt SP, Hendrix CW, Wolf SF, • Shearer GM, Henkart PA: Type 1/type 2 cytokine modulation of T-cell programmed cell death as a model for human immunodeficiency virus pathogenesis. Proc Natl Acad Sci U S A 1994, 91:11811-11815. This paper demonstrates that exogenous type 1 and type 2 cytokines can modulate T-cell-programmed cell death in T cells from HIV-infected donors. A role for endogenously produced cytokines is suggested by the inhibition of T-cell receptor-mediated death by antibodies against interleukin-4 and interleukin-10, and its enhancement by anti-interleukin-12 antibodies.
51. Radrizzani M, Accomero P, Amidei A, Aiello A, Delia D, Kurrle R, Colombo MP: IL-12 inhibits apoptosis Induced In a human Th1 clone by gp120/CD4 cross-linking and CD3/TCR activation or by IL-2 deprivation. Cell Immunol 1995, 161:14-21.
52. Estaquier J, Idziorek T, Zou W, Emilie D, Farber CM, Bourez JM, Ameisen JC: T helper type 1/T helper type 2 cytokines and T cell death: preventive effect of interleukin 12 on activation-induced and CD95 (Fas/Apo-1)-mediated apoptosis of CD4+ T cells from human Immunodeficiency virus-infected persons. J Exp Med 1995, 182:1759-1767.
53. Zhang M, Gately MK, Wang E, Gong J, Wolf SF, Lu S, Modlin RL, Barnes PF: Interleukin 12 at the site of disease in tuberculosis. J Clin Invest 1994, 93:1733-1739.
54. + type 2 T-cell clones from lepromatous lesions. Furthermore, it reports the presence of numerous interleukin-12-positive cells in tuberculoid lesions, in contrast to lepromatous lesions, in which these cells were rare. This paper indicates that interleukin-12 is an important mediator in the control of leprosy.
55. Soiffer RJ, Robertson MJ, Murray C, Cochran K, Ritz J: Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. Blood 1993, 82:2780-2796.
56. Ogata K, Tamura H, Yokose N, An E, Dan K, Hamaguchi H, Sakamaki H, Onozawa Y, Clark SC, Nomura T: Effects of interleukin-12 on natural killer cell cytotoxicity and the production of Interferon-gamma and tumour necrosis factor-alpha In patients with myelodysplastic syndromes. Br J Haematol 1995, 90:15-21.
57. Rook AH, Kubin M, Cassin M, Vonderheid EC, Vowels BR, Wolfe JT, Wolf SF, Singh A, Trinchieri G, Lessin SR: IL-12 reverses cytokine and Immune abnormalities In Sezary syndrome. J Immunol 1995, 154:1491-1498.
58. Afonso LC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, Scott P: The adjuvant effect of interleukin-12 in a vaccine against Leishmanla major. Science 1994, 263:235-237.
59. Wynn TA, Cheever AW, Jankovic D, Poindexter RW, Caspar P, Lewis FA, •• Sher A: An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature 1995, 376:594-596. The authors demonstrated that sensitization with eggs plus interleukin-12 partly inhibits granuloma formation and reduces the tissue fibrosis induced by natural infection with S. mansoni worms. Sensitization with eggs plus interleukin-12 converted the helminth-induced interleukin-12 response to a Th1-dominant pattern. This study is the first example of a vaccine against parasites acting by preventing pathology rather than infection.
60. Schijns VE, Haagmans BL, Horzinek MC: IL-12 stimulates an antiviral type 1 cytokine response but lacks adjuvant activity in IFN-gamma-receptor-deficient mice. J Immunol 1995, 155:2525-2532.
61. Noguchi Y, Richards EC, Chen YT, Old LJ: Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci U S A 1995, 92:2219-2223.
62. Benson J, Chougnet C, Tartaglia J, Shearer G, Paoletti E, Gallo R, Franchini G: Immunogenicity of a NYVAC/SIV vaccine in combination with IL-12 and IL-2 in rhesus macaques. AIDS Res Hum Retroviruses 1995, 11:5147.
63. Ozmen L, Pericin M, Hakimi J, Chizzonite RA, Wysocka M, Trinchieri G, Gately M, Garotta G: Interleukin 12, Interferon gamma, and tumor necrosis factor alpha are the key cytokines of the generalized Shwartzman reaction. J Exp Med 1994, 180:907-915.
64. Leonard JP, Waldburger KE, Goldman SJ: Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12- J Exp Med 1995, 181:381-386.
65. + cells into the islets. These infiltrating T cells were Th1 cells, expressing high levels of interferon gamma and low levels of interleukin-4.
66. Cancer trial of interleukin-12 halted. Science 1995, 268:1555.
67. IL-12 deaths: explanation and a puzzle. Science 1995, 270:908.
68. Wynn TA, Jankovic D, Hieny S, Zioncheck K, Jardieu P, Cheever AW, Sher • A: IL-12 exacerbates rather than suppresses T helper 2-dependent pathology In the absence of endogenous IFN-gamma. J Immunol 1995, 154:3999-4009. Interferon gamma knockout mice injected with schistosome eggs developed significantly larger granulomas than normal mice. In these mice, recombinant interleukin-12 treatment exacerbated the egg-induced response, augmented IgE levels, and did not reduce tissue eosinophilia. These results suggest that interferon gamma is clearly necessary for the suppressive effects of interleukin-12 on Th2 responses.
69. Foli A, Saville MW, Baseler MW, Yarchoan R: Effects of the Th1 and Th2 stimulatory cytokines interteukin-12 and interleukin-4 on human immunodeficiency virus replication. Blood 1995, 85:2114-2123.
70. Marshall JD, Secrist H, DeKruyff RH, Wolf SF, Umetsu DT: IL-12 inhibits the production of IL-4 and IL-10 in allergen-specific human CD4+ T lymphocytes. J Immunol 1995, 155:111-117.